For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women(Phase IV)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Colecalciferol/risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Sep 2013 New trial record